Pacira BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pacira BioSciences, Inc.
Flexion’s Zilretta is forecast to have big market potential with the growth of osteoarthritis, and Pacira’s CEO suggested there were commercial synergies with its Iovera device.
The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.
Keeping Track: Zegalogue Joins Hypoglycemia Space; Keytruda Earns First-Line Esophageal Cancer Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.
- Specialty Pharmaceuticals
- Controlled Release
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Blue Acquisition Corp.
- DepoTech Corp.
- myoscience, Inc.
- Pacira CryoTech, Inc.
- Pacira Pharmaceuticals, Inc.
- SkyePharma Inc.